menu
    • menu
    [{"orgOrder":0,"company":"Cali Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Ropivacaine Hydrochloride","moa":"Sodium channel alpha subunits","graph1":"Neurology","graph2":"Phase II","graph3":"Cali Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Extended Release Injection","sponsorNew":"Cali Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cali Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Cali Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Ropivacaine Hydrochloride","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"Cali Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Cali Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cali Biosciences \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Cali Biosciences

    Menu

    Cali Biosciences

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Cali Biosciences

                            China arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Cali Biosciences

                            China arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ropivacaine Hydrochloride

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Cali Biosciences Initiates Phase III Studies of CPL-01 (Long-Acting Ropivacaine) to Decrease Post-Operative Pa...

                            Details : CPL-01 is an extended-release injectable formulation of Naropin® (ropivacaine hydrochloride), which is a member of the amino amide class of local anesthetics indicated for the production of local or regional anesthesia for surgery and acute pain managem...

                            Brand Name : CPL-01

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 18, 2023

                            Lead Product(s) : Ropivacaine Hydrochloride

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Cali Biosciences

                            China arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Cali Biosciences

                            China arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ropivacaine Hydrochloride

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Cali Biosciences Announces Successful Results in Phase IIb Study of Long-Acting Ropivacaine (CPL-01) for Non-O...

                            Details : In the dose currently planned as the to-be marketed dose, 14 subjects who received CPL-01 showed a mean AUC through 72 hours of wWOCF adjusted NRS-A of 286.8, showing a trend towards significance against the 13 subjects who received placebo.

                            Brand Name : CPL-01

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 21, 2022

                            Lead Product(s) : Ropivacaine Hydrochloride

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth